Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk – Combined results from two screening trials

Clinical Cancer Research

Volumn 23, Issue 14, 2017, Pages 3628-3637

  Skates, Steven J ^a   Greene, Mark H ^b   Buys, Saundra S ^c   Mai, Phuong L ^b   Brown, Powel ^d   Piedmonte, Marion ^e   Rodriguez, Gustavo ^f   Schorge, John O ^a   Sherman, Mark ^b   Daly, Mary B ^g   Rutherford, Thomas ^h   Brewster, Wendy R ⁱ   O'Malley, David M ^j   Partridge, Edward ^k   Boggess, John ^l   Drescher, Charles W ^m   Isaacs, Claudine ⁿ   Berchuck, Andrew ^o   Domchek, Susan ^p   Davidson, Susan A ^q   Edwards, Robert ^r   Elg, Steven A ^s   Wakeley, Katie ^t   Phillips, Kelly Anne ^u,v,w   Armstrong, Deborah ^x   Horowitz, Ira ^y   Fabian, Carol J ^z   Walker, Joan ^aa   Sluss, Patrick M ^a   Welch, William ^ab   Minasian, Lori ^b   Horick, Nora K ^a   Kasten, Carol H ^ac   Nayfield, Susan ^ad   Alberts, David ^ae   Finkelstein, Dianne M ^a   Lu, Karen H ^d   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l Rex Cancer Center   (United States)

^m Fred Hutchinson Cancer Research Center   (United States)

ⁿ GEORGETOWN UNIVERSITY   (United States)

^o DUKE UNIVERSITY MEDICAL CENTER   (United States)

^p UNIVERSITY OF PENNSYLVANIA   (United States)

^q DENVER HEALTH MEDICAL CENTER   (United States)

^r UNIVERSITY OF PITTSBURGH   (United States)

^s Iowa Clinic   (United States)

^t South Shore Hospital   (United States)

^u PETER MACCALLUM CANCER CENTRE   (Australia)

^v UNIVERSITY OF MELBOURNE   (Australia)

^w UNIVERSITY OF MELBOURNE   (Australia)

^x JOHNS HOPKINS UNIVERSITY   (United States)

^y EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^z UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^aa UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^ab BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ac CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^ad UNIVERSITY OF FLORIDA   (United States)

^ae UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; ORAL CONTRACEPTIVE AGENT; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

ALGORITHM; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; BREAST CANCER; CA 125 ANTIGEN BLOOD LEVEL; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; GOLD STANDARD; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; RISK ASSESSMENT; RISK OF OVARIAN CANCER ALGORITHM; RISK REDUCTION; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TUMOR SUPPRESSOR GENE; ADULT; AGED; BLOOD; BREAST TUMOR; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RISK FACTOR;

ADULT; AGED; ALGORITHMS; BREAST NEOPLASMS; CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 85014912406     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2750     Document Type: Article

References (47)

1. Trimble EL. The NIH Consensus Conference on Ovarian Cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55:S1–3.
2. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA 1997;277:997–1003.
3. Cancer Australia. Surveillance of women at high or potentially high risk of ovarian cancer; 2009[cited 2016 May 16]; Available from:https://canceraustralia.gov.au/publications-and-resources/position-statements/surveillance-women-high-or-potentially-high-risk-ovarian-cancer.
4. Daly MB, Axilbund JE, Buys S, Crawford B, Friedman S, Garber JE, et al. Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Version 1.2012); 2012 [Cited: 2016 May 16]. Available from:http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp#detection.
5. Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, et al. Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Version 2.2016); 2016. [Cited: 2016 May 16] Available from:https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
6. Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dorum A, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2009;46:593–7.
7. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 2007;114:1500–9.
8. Dorum A, Heimdal K, Lovslett K, Kristensen G, Hansen LJ, Sandvei R, et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999;78:906–11.
9. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging [see comments]. BMJ 1993;306:1025–9.
10. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20–6.
11. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22:1315–27.
12. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013;31:49–57.
13. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413–6.
14. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260–5.
15. Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76:2004–10.
16. Skates SJ, Pauler DK, Jacobs IJ. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point and mixture models of longitudinal markers. J Am Stat Assoc 2001;96:429–39.
17. McIntosh MW, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 2003;4:27–40.
18. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) 2011;4:1401–8.
19. Daly MB, Axilbund JE, Buys S, Crawford B, Friedman S, Garber JE, et al. Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology; 2012.
20. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol 2015;213:262–7.
21. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011; 305:2295–303.
22. Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355–8.
23. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207–10.
24. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919–26.
25. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327–40.
26. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 2014;121:35–9.
27. Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 2008;17:594–604.
28. Skates SJ. Clinical trial to screen participants who are at high genetic risk for ovarian cancer - NCT00039559; 2001 [Cited: 2016 May 16]. Available from:http://www.ClinicalTrials.gov/ct2/show/NCT00039559.
29. Kauff ND, Mitra N, Robson ME, Hurley KE, Chuai S, Goldfrank D, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005;97:1382–4.
30. Domchek SM, Stopfer JE, Rebbeck TR. Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Compr Canc Netw 2006;4:177–82.
31. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 2014;32:3275–83.
32. R Core Team. R: A language and environment for statistical computing; 2015.[Cited: 2016 May 16] Available from:http://www.R-project.org.
33. Grover S, Quinn MA, Weideman P, Koh H, Robinson HP, Rome R, et al. Screening for ovarian cancer using serum CA125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer 1995;5:291–5.
34. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history [see comments]. J Natl Cancer Inst 1997;89:227–38.
35. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the united kingdom collaborative trial of ovarian cancer screening. J Clin Oncol 2015;33:2062–71.
36. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011:CD007565.
37. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–59.
38. Ingham SL, Warwick J, Buchan I, Sahin S, O'Hara C, Moran A, et al. Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. J Med Genet 2013;50:368–72.
39. Mongia SK, Rawlins ML, Owen WE, Roberts WL. Performance characteristics of seven automated CA 125 assays. Am J Clin Pathol 2006; 125:921–7.
40. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26–35.
41. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26:5284–93.
42. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40–6.
43. Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010; 19:2995–9.
44. Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih Ie M, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4.
45. Erickson BK, Kinde I, Dobbin ZC, Wang Y, Martin JY, Alvarez RD, et al. Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obst Gynecol 2014;124: 881–5.
46. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945–56.
47. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967–75.